Biotherapeutics and reagents developer Avacta Group said chief scientific officer Amrik Basran would present at a conference in Lisbon this week.

Basran would on Wednesday present recent data from pre-clinical development of the company's lead therapeutic programme, at the Protein Engineering Society of Europe meeting.

Avacta said it was developing a single-molecule bi-specific therapy with a view to entering phase I clinical development in 2020.


At 1:43pm: (LON:AVCT) Avacta Group PLC share price was 0p at 24.1p